9 July 2021
Prof. Dr. David Alan Rizzieri Appointed Editor-in-Chief of Journal of Personalized Medicine
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
We are pleased to announce that Prof. Dr. David Alan Rizzieri has been appointed Editor-in-Chief of Journal of Personalized Medicine (ISSN 2075-4426).
Prof. Dr. Rizzieri, MD, is a medical oncologist at the Duck Cancer Institute in Durham, NC, USA, and has over 30 years of experience in the medical field. He graduated from the University of Rochester School of Medicine in 1991. He is affiliated with Duke University Hospital.
He has been a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and is a member of the ALLIANCE (formerly CALGB) Leukemia Core Committee. He has served as chair or co-chair of multiple ALLIANCE lymphoma/ leukemia trials. He has led a team’s novel approaches for the care of patients using non-myeloablative allogeneic therapy to optimize a less toxic regimen for the transplant of patients with hematologic malignancies using haplo-identical, as well as matched donors. Furthermore, he has served on various NIH/NHLBI grant review committees and the ASH sub-committee on government affairs. He oversees the development and conduct of all clinical trials in adults with hematologic malignancies conducted in the Duke Cancer Institute. In recognition of his leadership and success in clinical research efforts, he was fortunate to receive the NIH “Clinical Investigator Team Leadership Award” in 2010 and was awarded the “Wendell Rosse Teaching Award” by the fellows in 2009.
He has published 457 peer-reviewed scientific papers with more than 10,000 citations. His research interests focus on the care of patients with hematologic malignancies, both with and without the use of bone marrow or stem cell transplantation. He focuses his research efforts on new approaches to manipulate minimal residual disease.
He will work closely with over 200 editorial board members from across the globe.
We warmly welcome Prof. Dr. David Alan Rizzieri in his role as Editor-in-Chief, and we look forward to him leading JPM to achieve more milestones.